Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: CureVac

Market Cap 867M 1B 799M 748M 1.4B 95.4B 1.42B 9.43B 3.68B 46.43B 3.77B 3.69B 161B P/E Ratio 2026 *
-
P/E Ratio 2027 * -
Enterprise Value 424M 491M 391M 366M 686M 46.67B 696M 4.61B 1.8B 22.72B 1.84B 1.8B 78.66B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day-0.21%
6 months-7.72%
Current year+3.10%
Current year 4.48
Extreme 4.48
4.68
1 year 4
Extreme 4.0001
5.58
3 years 2.22
Extreme 2.215
12.36
5 years 2.22
Extreme 2.215
101
10 years 2.22
Extreme 2.215
151.8
Manager TitleAgeSince
Chief Executive Officer 56 2023-03-27
Chief Tech/Sci/R&D Officer 60 -
Chief Operating Officer 61 2021-06-30
Director TitleAgeSince
Chairman 75 2015-07-31
Director/Board Member 58 2015-07-31
Director/Board Member 60 2019-05-31

Financials

2026 *2027 *
Net sales - -
Net income -132M -153M -122M -114M -214M -14.57B -217M -1.44B -562M -7.09B -575M -563M -24.56B -
Net Debt - -
Logo CureVac
CureVac NV, formerly CureVac AG, is a Germany-based clinical-stage biopharmaceutical company. The Company develops transformative medicines based on messenger ribonucleic acid, or mRNA. The Company's mRNAs are designed to prevent infections and to treat diseases by mimicking human biology to synthesize the desired proteins. Its technology platform optimizes mRNA constructs that encode functional proteins which either induce a desired immune response or replace defective or missing proteins using the cell’s intrinsic translation machinery. The Company's product portfolio includes clinical and preclinical candidates across multiple disease indications in prophylactic vaccines, oncology, and molecular therapy. In prophylactic vaccines, the Company is advancing its second-generation mRNA backbone against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and a range of infectious diseases, including seasonal influenza, in collaboration with GSK(Glaxo Smith Kline).
Employees
904
Sector
-
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. CVAC Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!